Guideline-Directed Medical Therapy
How effective is GDMT for treating heart failure?
Contents
What is Guideline-Directed Medical Therapy (GDMT)?
Guideline-Directed Medical Therapy, or GDMT, is a combination of evidence-based medications proven in large clinical trials to improve survival and reduce hospitalizations in people with heart failure.
GDMT is primarily used to treat heart failure with reduced ejection fraction (HFrEF), though some of its medications are also indicated for heart failure with preserved ejection fraction (HFpEF).
Today’s foundational four-drug regimen (also known as the “four pillars”) for HFrEF typically includes:
A beta blocker
A mineralocorticoid receptor antagonist (MRA)
A renin-angiotensin-aldosterone system (RAAS) inhibitor
A sodium-glucose co-transporter 2 (SGLT2) inhibitor.
For certain patients, an additional combination of hydralazine and nitrates may also be recommended, particularly when symptoms persist despite optimal therapy or when RAAS inhibitors are not well tolerated.
In this post, we’ll focus on how effective GDMT can be. For more background on this medication regimen, check out our related post on heart failure.
How Effective Is GDMT in Heart Failure With Reduced Ejection Fraction (HFrEF)?
Heart failure with reduced ejection fraction (HFrEF) means the heart’s main pumping chamber is weakened and cannot squeeze effectively.
For patients with HFrEF, the estimated risk of death at two years without GDMT is about 20-50%. With a four-drug GDMT regimen at target doses, that risk drops below 15%. It has also been shown that patients who consistently take their multi-drug GDMT regimen have a 37% lower mortality risk compared to patients not on GDMT.
A recent study looked at whether modern GDMT has changed the long-held view that HF and cancer carry similar mortality rates. The results suggest it has. Patients with HFrEF treated with GDMT that included angiotensin receptor–neprilysin inhibitors (ARNIs) had significantly better survival than patients with cancer. Those treated with ACE inhibitors instead of ARNIs also lived longer than cancer patients, though the benefit was smaller. In contrast, patients with HFrEF who were not on GDMT had higher mortality than patients with cancer. Among common sex-specific cancers, only prostate and breast cancer had better survival than HFrEF treated with GDMT.
Overall, modern HF therapy, especially GDMT regimens that include ARNIs, substantially improve survival.
GDMT recommendations are based on decades of large clinical trials. Over time, these studies have consistently shown that GDMT helps people with HFrEF live longer and stay out of the hospital. Some of the key landmark studies include:
1987: CONSENSUS showed that enalapril (RAAS) was associated with a 31% reduction in HF mortality at 1-year compared to placebo.
1991: SOLVD showed that enalapril (RAAS) was associated with a 23% reduction in mortality and a 30% reduction in the risk of hospitalization or death.
1996: COPERNICUS showed a 35% decrease in the risk of death with carvedilol (beta blocker).
1999: MERIT-HF showed that metoprolol succinate (beta blocker) added to optimum standard treatment lessened all-cause mortality by 34% in clinically stable patients with HFrEF in NYHA functional classes II-IV.
1999: RALES showed that spironolactone (MRA) lowered mortality by about 30% in patients with class IV heart failure.
2014: PARADIGM-HF found that sacubitril/valsartan (RAAS) reduced cardiovascular death and heart failure hospitalization more than enalapril.
2019: DAPA-HF showed the risk of worsening HF or death from cardiovascular causes was lower among those who received dapagliflozin (SGLT2) than among those who received placebo, regardless of the presence or absence of diabetes.
2020: EMPEROR-Reduced showed that empagliflozin (SGLT2) lowered the risk of death from cardiovascular causes or hospitalization for heart failure from 24.7% in the placebo group to 19.4% in the treatment group, even in patients without diabetes.
When used together and titrated carefully to target doses, these medications provide additive benefit. The key is not just prescribing them, but titrating (adjusting) them regularly over time to reach evidence-based dosing while monitoring labs, symptoms, and vitals like blood pressure and heart rate.
If you’d like to read more, the American College of Cardiology, American Heart Association, and Heart Failure Society of America work together to publish clear guidelines that walk through the recommended treatment options for people living with HFrEF.
What Does Hospitalization Tell Us About Heart Failure?
A hospitalization for heart failure is often a sign that the condition is more advanced or harder to manage. Patients who have been hospitalized have a higher risk of complications:
About 60% of patients are readmitted within a year of discharge.
The good news is that close outpatient follow-up and careful medication management can help reduce these risks. Early follow-up visits, lab monitoring, and gradual medication dose adjustments can improve stability and lower the chance of repeat hospitalization and death.
Heart failure treatment is not “one and done.” Hospitalization typically highlights the need for proactive, ongoing care to keep patients as healthy and stable as possible.
What About Heart Failure With Preserved Ejection Fraction (HFpEF)?
Heart failure with preserved ejection fraction (HFpEF) occurs when the heart’s pumping strength is normal, but the heart is stiff and does not relax properly.
Historically, treatment options for HFpEF were limited. For many years, large trials of ACE inhibitors, ARBs, and MRAs showed mixed or modest benefit. As a result, management focused mainly on controlling blood pressure, managing fluid status, and treating comorbidities such as atrial fibrillation, diabetes, and obesity.
That changed with the introduction of SGLT2 inhibitors:
2021: EMPEROR-Preserved showed that empagliflozin (SGLT2) reduced the combined risk of the composite of cardiovascular death or hospitalization by 21%, which was mainly related to a 29% lower risk of hospitalization.
2022: DELIVER showed dapagliflozin (SGLT2) resulted in a lower risk of the primary composite outcome (worsening heart failure or cardiovascular death), in fewer worsening heart failure events and cardiovascular deaths, and in a lower symptom burden.
There is also evidence that ARB (RAAS), ARNi (RAAS), and MRA medications can help improve symptoms and reduce hospitalizations for people with HFpEF, though the survival benefit is not as clear.
2003: CHARM-preserved showed that candesartan (ARB) did not lower cardiovascular death, but did lower HF hospitalizations.
2014: TOPCAT showed that treatment with spironolactone (MRA) did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure; however it did significantly lower the incidence of hospitalization.
2019: PARAGON-HF showed sacubitril/valsartan (RAAS) is associated with fewer hospitalizations and improvement in NYHA class.
For more information, the Journal of the American College of Cardiology has a detailed guideline of treatment options for people with HFpEF.
These trials marked a turning point. For the first time, we had medications clearly shown to improve outcomes in HFpEF. While the mortality benefit of GDMT is not as dramatic in HFpEF as in HFrEF, these medications can improve symptoms and reduce hospitalizations.
Takeaways
GDMT is one of the most powerful tools we have in heart failure management and is a strong example of how the right combination of medications can improve outcomes. When fully implemented, GDMT can substantially reduce the risk of death and improve quality of life in people with HFrEF; and newer therapies are now improving quality of life and reducing hospitalizations for people with HFpEF.
The most important factor is not just starting medications, but:
Starting them early
Using the right combination
Titrating to target doses
Staying in close communication with your care team to track progress and address concerns
At Empallo, we focus on timely follow-up, careful medication adjustment, and clear communication so patients understand their plan and feel confident in their care. Heart failure is serious, but with the right therapy and close monitoring, outcomes can improve significantly.
This content is for general informational purposes only and is not medical advice. Talk with your healthcare provider before making any decisions about your health.
